Navigation Links
Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows

Results from Phase One of Two-Phase Examination of U.S. Asthma Control

RESEARCH TRIANGLE PARK, N.C. and TORONTO, May 20 /PRNewswire-FirstCall/ -- Nearly half of adult Americans with asthma and more than a quarter of children with asthma who responded to a nationally representative survey do not have their disease well controlled, according to the Asthma USA survey, which was presented today at the International Conference of the American Thoracic Society meeting in Toronto.

The survey found that not well controlled asthma had significant medical consequences. Adults with uncontrolled asthma were more likely to require treatment with oral corticosteroids, visit the emergency department or be admitted to the hospital than those whose asthma was well controlled. Children with uncontrolled asthma were also more likely to require urgent medical care. Past research has shown that uncontrolled asthma can put patients at risk for increased asthma symptoms, sudden asthma attacks, hospitalizations and even death.

"We have made quantum leaps in asthma treatment in the last decade, but the Asthma USA results demonstrate that enormous numbers of patients are living with asthma that is still not well controlled, putting them at significant health risk," said David Stempel, MD, director of clinical medicine for GlaxoSmithKline. "These findings remind us that improvements in care have not been uniform and underscore the critical need to improve education for both patients and healthcare providers in the management of asthma."

According to the National Institutes of Health Guidelines for the Diagnosis and Management of Asthma, signs of poor asthma control include waking at night with asthma symptoms, trips to the hospital and the need for quick-relief medication such as albuterol more than twice a week for asthma symptoms.

The survey examined responses from more than 81,500 households, with asthma control assessed with the Asthma Control Test(TM) (ACT), a validated assessment questionnaire recommended by national treatment guidelines for determining a patient's level of asthma control. Of the more than 10,000 adults with self-reported asthma taking the ACT, 41 percent had a score of 19 or less, which indicates not well controlled asthma.

The survey also examined scores from the Childhood Asthma Control Test and ACT to determine the level of asthma control in more than 3,000 children respondents* between the ages of 4 and 17 and found that asthma control in children is also deficient. According to the findings, 31 percent of children with asthma between the ages of 4 and 11 and 25 percent of those between 12 and 17 did not have well-controlled asthma.

About the Asthma USA Survey

The Asthma USA study was conducted by GlaxoSmithKline in cooperation with National Family Opinion Survey Group and designed to evaluate uncontrolled asthma and assess demographic variables associated with asthma risk in the general population of the United States.

This was a cross sectional mailed survey administered to a representative national sample of 134,401 households recruited from a consumer panel of households managed by NFO/TNS in May, June and July 2007, a time when asthma-related medical complications traditionally see a seasonal decline. Surveys were returned for 60.6 percent of households, including information on 10,139 adults with a self-reported physician diagnosis of asthma completing the Asthma Control Test. Data for 38,323 children aged 4 to 17 was returned with a total of 1,991 children 4 to 11 years with asthma and 1,265 adolescents 12-17 years with asthma included in the survey.

The data presented at the ATS meeting represents the first phase of the study which is the baseline data. A subset of the initial population will be followed on a quarterly basis to generate longitudinal data on asthma control, missed work and school, medication use and seasonal variation in asthma control.

About Asthma

Asthma is a chronic lung disease. Research has established that the two main components of asthma are inflammation (swelling and excess mucus build-up in the airways) and bronchoconstriction (tightening of the muscles surrounding the airways). Treating both components is necessary for many patients to achieve optimal asthma control.

Asthma symptoms include shortness of breath, wheezing, chest tightness, or cough. Other signs of asthma can include a persistent cough at night; difficulty breathing during, or soon after, physical exertion or exercise; or waking up at night because of one or more of these symptoms. Asthma is unpredictable. Asthma symptoms may seem mild or even nonexistent, but they can flare up and be severe at any time.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit

*The Childhood Asthma Control Test is for children 4 to 11 years of age to complete with their parents or guardians.

The Asthma Control Test is a trademark of QualityMetric Incorporated.

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
2. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
3. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
4. One Year On, ALLERCA Hypoallergenic Cats Bring Sneeze Free Companionship to Allergy and Asthma Sufferers
5. AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
6. Drug Reduces Airway Mucus in Preclinical Asthma Model
7. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
8. Allergy Standards LTD to Attend 2008 American Academy of Allergy, Asthma and Immunology Conference
9. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
10. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
11. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
Post Your Comments:
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
Breaking Biology News(10 mins):